Informations

During the 2026 European Association of Urology (EAU) Congress, Prof. Saad M.A. from the Department of Medical Oncology at the Mohammed V Military Teaching Hospital, Rabat, Morocco, presented a systematic review and reconstructed Individual Patient Data (IPD) meta-analysis. The study evaluated the clinical value of Bacillus Calmette-Guérin (BCG) combined with Immune Checkpoint Inhibitors (ICIs) in…

During the recent academic session, Professor Antoine Van Der Heijden from Radboud University Medical Center (Nijmegen, NL) shared comprehensive insights into the management of Muscle-Invasive Bladder Cancer (MIBC). The presentation focused on the clinical significance of histological subtypes, the inherent limitations of traditional Transurethral Resection of Bladder Tumor (TURBT), and the emerging value of MRI…

During a recent academic session, Professor Dingwei Ye (Prof. Dingwei Ye) from Fudan University Shanghai Cancer Center provided an in-depth interpretation of the Phase 1/2 clinical study data for SIM0237—an anti-PD-L1/IL-15 variant fusion protein—specifically in patients with Bacillus Calmette-Guérin (BCG)-unresponsive high-risk non-muscle-invasive bladder cancer (NMIBC).

During the recent ASCO GU 2025 (Genitourinary Cancers Symposium), Professor Jiwei Huang from Renji Hospital, Affiliated to Shanghai Jiao Tong University School of Medicine (on behalf of the research team led by Ding Yingjie), presented the updated efficacy and safety data from a multicenter, single-arm, Phase II trial. The study evaluates the combination of Fruquintinib…

During a recent session on urological oncology, Professor A. Ślusarczyk from the Department of General, Oncological, and Functional Urology at the Medical University of Warsaw, Poland, presented the results of an international multicenter retrospective study. The study aimed to develop and validate a clinical predictive model to identify patients with high-grade non-muscle-invasive bladder cancer (NMIBC)…

Dr. Biagio Antonio Maiorano from the Department of Medical Oncology, IRCCS San Raffaele Hospital (Milan, Italy), presented a sub-analysis of the ARON-1 study. This analysis evaluated the real-world incidence of grade 3–4 adverse events (AEs) and their clinical impact on overall survival (OS) in patients with metastatic renal cell carcinoma (mRCC) receiving first-line immune checkpoint…

At a recent academic symposium, Professor Joan Palou from the Department of Urology, Universitat Autònoma de Barcelona, Spain, presented the latest subgroup analysis from the POTOMAC study. The presentation focused on the efficacy and safety of one year of durvalumab (D) in combination with Bacillus Calmette-Guérin (BCG) induction and maintenance therapy for BCG-naïve, high-risk non-muscle-invasive…

During a recent session on urological oncology, Professor A. Ślusarczyk from the Department of General, Oncological, and Functional Urology at the Medical University of Warsaw, Poland, presented the results of an international multicenter retrospective study. The study aimed to develop and validate a clinical predictive model to identify patients with high-grade non-muscle-invasive bladder cancer (NMIBC)…